A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

Brief description of study

    The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

    Eligibility of study

    You may be eligible for this study if you meet the following criteria:

    • Conditions:
      IgAN,primary immunoglobulin A nephropathy
    • Age: Between 1 Years - 100 Years
    • Gender: All


    Updated on 26 Feb 2020. Study ID: 833614

    Interested in the study

    Select a study center that’s convenient for you, and get in touch with the study team.

    Contact a study center